Skip to main content
. 2019 Jan 31;5(5):623–632. doi: 10.1001/jamaoncol.2018.6607

Figure 2. Survival.

Figure 2.

A, Prostate-specific antigen (PSA) progression-free survival in 79 patients receiving androgen-deprivation therapy (ADT) plus docetaxel and 81 receiving ADT alone. Median follow-up, 30.0 months (ADT plus docetaxel, 20.3 [95% CI, 19.0-21.6]; ADT alone: 19.3 months [95% CI, 18.2-20.8]); hazard ratio [HR], 0.85 (95% CI, 0.62-1.16); P = .31. B, Radiologic progression-free survival (including deaths from cancer) in 72 patients receiving ADT plus docetaxel and 69 receiving ADT alone. Median follow-up for ADT plus docetaxel, 8.9 years (7.3-10.2); ADT alone, 9.0 years (range, 7.3-10.4); HR 1.03 (95% CI, 0.74-1.43); P = .88. C, Overall all-cause survival in 40 patients receiving ADT plus docetaxel and 46 receiving ADT alone. Median follow-up, 10.5 years; 25th percentile, ADT plus docetaxel, 8.7 years (6.7-10.2); ADT alone, 7.8 years (6.2-9.3); 12-year survival rate, ADT plus docetaxel, 60% (not reached, 70%); ADT alone, 55% (NR, 65%); HR, 0.86 (95% CI, 0.56-1.31); P = .49. Dashed lines indicate 50% (median) and 75% (25th percentile).